Of note, AXL inhibition using bemcentinib could only partially restore tumor cell sensitivity to lymphocyte-mediated lysis, suggesting that additional factors mediate immune resistance and evasion of these carcinoma cells. The gene discussed is AXL; the disease is carcinoma.